Effects of nitro-L-arginine on blood pressure and cardiac index in anesthetized rats: A pharmacokinetic-pharmacodynamic analysis

Pharmaceutical Research

Volumn 15, Issue 7, 1998, Pages 1063-1068

  Tabrizi Fard, Mohammad A ^a   Fung, Ho Leung ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Hemodynamic effects; Nitric oxide (NO); Nitric oxide synthesis (NO); Nitro L arginine (L NA); Pharmacodynamics (PD); Pharmacokinetics (PK)

Indexed keywords

N(G) NITROARGININE; NITRIC OXIDE SYNTHASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DETERMINATION; HEART RATE; HEMODYNAMICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTRAVENOUS DRUG ADMINISTRATION; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; RAT; SYSTEMIC VASCULAR RESISTANCE;

ANESTHESIA; ANIMALS; BLOOD PRESSURE; BODY WEIGHT; CARDIAC OUTPUT; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HEART RATE; INFUSIONS, INTRAVENOUS; MALE; NITRIC OXIDE SYNTHASE; NITROARGININE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0031820908     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011986312541     Document Type: Article

References (25)

1. S. Moncada and E. A. Higgs. Molecular mechanisms and therapeutic strategies related to nitric oxide. FASEB J. 9:1319-30 (1995).
2. A. Petros, G. Lamb, A. Leone, S. Moncada, D. Bennett, and P. Vallance. Effects of a nitric oxide synthase inhibitor in humans with septic shock. Cardiovas. Res. 28:34-9 (1994).
3. J. A. Lorente, L. Landin, R. De Pablo, E. Renes, and D. Liste. L-arginine pathway in the sepsis syndrome. Crit. Care Med. 21:1287-95 (1993).
4. R. E. Klabunde, R. C. Ritger, and M. C. Helgren. Cardiovascular actions of inhibitors of endothelium-derived relaxing factor (nitric oxide) formation/release in anesthetized dogs. Eur. J. Pharmacol. 199:51-9 (1991).
5. R. G. Kilbourn, C. Szabo, and D. L. Traber. Beneficial versus detrimental effects of nitric oxide synthase inhibitors in circulatory shock: lessons learned from experimental and clinical studies. Shock 7:235-46 (1997).
6. E. A. Minnard, J. Shou, H. Naama, A. Cech, H. Gallagher, and J. M. Daly. Inhibition of nitric oxide synthesis is detrimental during endotoxemia. Arch. Surg. 129:142-7 (1994).
7. F. M. Robertson, P. J. Offner, D. P. Ciceri, W. K. Becker, and B. A. Pruitt, Jr. Detrimental hemodynamic effects of nitric oxide synthase inhibition in septic shock. Arch. Surg. 129:149-55 (1994).
8. M. A. Tabrizi-Fard and H. L. Fung. Reversed-phase high-performance liquid chromatography method for the analysis of nitroarginine in rat plasma and urine. J. Chromatog. B: Biom. Applica. 679:7-12 (1996).
9. D. Verotta and L. B. Sheiner. Simultaneous modeling of pharmacokinetics and pharmacodynamics: an improved algorithm. CABIOS 3:345-9 (1987).
10. J. D. Unadkat, F. Bartha, and L. B. Sheiner. Simultaneous modeling of pharmacokinetics and pharmacodynamics with nonparametric kinetic and dynamic models. Clin. Pharmacol. Ther. 40:86-93 (1986).
11. L. B. Sheiner, D. R. Stanski, S. Vozeh, R. D. Miller, and J. Ham. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin. Pharmacol. Ther. 25:358-71 (1979).
12. W. G. Haynes, J. P. Noon, B. R. Walker, and D. J. Webb. Inhibition of nitric oxide synthesis increases blood pressure in healthy humans. J. Hypertension. 11:1375-80 (1993).
13. H. M. Vargas, J. M. Cuevas, L. J. Ignarro, and G. Chaudhuri. Comparison of the inhibitory potencies of N(G)-methyl-, N(G)-nitro- and N(G)-amino-L-arginine on EDRF function in the rat: evidence for continuous basal EDRF release. Journal of Pharmacology & Experimental Therapeutics. 257:1208-15 (1991).
14. N. H. Holford and L. B. Sheiner. Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin. Pharmacokin. 6:429-53 (1981).
15. W. J. Jusko and H. C. Ko. Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clin. Pharmacol. Ther. 56:406-19 (1994).
16. P. Klatt, K. Schmidt, F. Brunner, and B. Mayer. Inhibitors of brain nitric oxide synthase. Binding kinetics, metabolism, and enzyme inactivation. J. Biol. Chem. 269:1674-80 (1994).
17. E. S. Furfine, M. F. Harmon, J. E. Paith, and E. P. Garvey. Selective inhibition of constitutive nitric oxide synthase by L-NG-nitroarginine. Biochemistry. 32:8512-7 (1993).
18. N. L. Dayneka, V. Garg, and W. J. Jusko. Comparison of four basic models of indirect pharmacodynamic responses. J. Pharmacokin. Biopharm. 21:457-78 (1993).
19. T. B. Tzeng and H. L. Fung. Pharmacodynamic modeling of the in vitro vasodilating effects of organic mononitrates. J. Pharmacokin. Biopharm. 20:227-51 (1992).
20. P. Vallance, J. Collier, and S. Moncada. Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet. 2:997-1000 (1989).
21. A. J. Brady, P. A. Poole-Wilson, S. E. Harding, and J. B. Warren. Nitric oxide production within cardiac myocytes reduces their contractility in endotoxemia. Am. J. Physiol. 263:H1963-6 (1992).
22. S. M. Gardiner, A. M. Compton, P. A. Kemp, and T. Bennett. Regional and cardiac haemodynamic effects of NG-nitro-L-argi-nine methyl ester in conscious, Long Evans rats. Brit. J. Pharmacol. 101:625-31 (1990).
23. J. Buelke-Sam, J. F. Holson, J. J. Bazare, and J. F. Young. Comparative stability of physiological parameters during sustained anesthesia in rats. Lab. Animl. Sci. 28:157-62 (1978).
24. M. A. Tabrizi-Fard and H. L. Fung. Pharmacokinetics, plasma protein binding and urinary excretion of N omega-nitro-L-arginine in rats. Brit. J. Pharmacol. 111:394-6 (1994).
25. M. A. Tabrizi-Fard and H. L. Fung. Pharmacokinetics and steady-state tissue distribution of L- and D-isomers of nitroarginine in rats. Drug Metab. Dispos. 24:1241-6 (1996).